Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Tipo de documento
Ano de publicação
Intervalo de ano de publicação
1.
Comb Chem High Throughput Screen ; 25(9): 1399-1410, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-34238150

RESUMO

BACKGROUND: PD-1/PD-L1 checkpoint inhibitors have been approved for the treatment of a variety of solid tumors. Some clinical trials have also confirmed the excellent efficacy of PD- 1/PD-L1 inhibitors on lymphoma. However, the efficacy of PD-1/PD-L1 inhibitors on leukemia remains unclear. INTRODUCTION: To understand the connection between PD-1/PD-L1 and leukemia better, this review concentrates on the up-regulated expression of PD-1/PD-L1 and the PD-1/PD-L1 blockade trials in participants with leukemia. PD-1/PD-L1 signal performs momentously negative immunoregulation of cancer, which can inhibit the activation of cytotoxic T cells and involve in the immune escape in tumors. Activated PD-1/PD-L1 may transduce negative intracellular signals to block the mitotic cycle and the development of T-cells. Several pathways are involved in these critical biochemical processes, including MAPK, calcium, PI3K/AKT, and so on. Lately, PD-1/PD-L1 antibodies have illustrated unprecedented curative effects on Hodgkin's lymphoma and some solid tumors. Specimens from patients with leukemia demonstrated the elevated level of PD-1/PD-L1 in T lymphocytes. This finding inspired hematologists to use PD-1/PD-L1 inhibitors for subjects suffering from leukemia. Some clinical trials have implied that PD-1/PD-L1 inhibitors could help patients fight against leukemia, however, other researchers have reported the opposite results. CONCLUSION: PD-1/PD-L1 is upregulated in leukemia, but the results regarding PD-1/PD-L1 blockade are mixed and more clinical trials are needed to be conducted.


Assuntos
Leucemia , Neoplasias , Antígeno B7-H1 , Humanos , Inibidores de Checkpoint Imunológico , Imunoterapia/métodos , Leucemia/tratamento farmacológico , Fosfatidilinositol 3-Quinases , Receptor de Morte Celular Programada 1/metabolismo
2.
Data Brief ; 37: 107248, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-34277901

RESUMO

Maintaining oral hygiene is very important for a healthy life. Poor toothbrushing is one of the leading causes of tooth decay and other gum problems. Many people do not brush their teeth properly. There is very limited technology available to help in assessing the quality of toothbrushing. Human Activity Recognition (HAR) applications have seen a tremendous growth in recent years. In this work, we treat the adherence to standard toothbrushing practice as an activity recognition problem. We investigate this problem and collect experimental data using a brush-attached and a wearable sensor when the users brush their teeth. In this paper, we extend our previous dataset [1] for toothbrushing activity by including more experiments and adding a new sensor. We discuss and analyse the collection of the dataset. We use an Inertial Measurement Unit (IMU) sensor to collect the time-series data for toothbrushing activity. We recruited 22 healthy participants and collected the data in two different settings when they brushed their teeth in five different locations using both electric and manual brushes. In total, we have recorded 120 toothbrushing sessions using both brush-attached sensor and the wearable sensor.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA